Bone Neoplasms

• 

  Subject Areas on Research

  • "Dedifferentiated" chordoma: a case report of the cytomorphologic findings on fine-needle aspiration. 
  • "Tips" on acute arthritis and clubbing. 
  • 211At- and 131I-labeled bisphosphonates with high in vivo stability and bone accumulation. 
  • 4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial. 
  • 5-Fluorouracil in childhood solid tumors. 
  • A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603). 
  • A case of curative-intent hepatectomy for colon cancer metastatic to the scapula and liver. 
  • A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease. 
  • A multiphase immunotherapy regimen for human melanoma: clinical and laboratory results. 
  • A mutant PTH/PTHrP type I receptor in enchondromatosis. 
  • A novel, non-apoptotic role for Scythe/BAT3: a functional switch between the pro- and anti-proliferative roles of p21 during the cell cycle. 
  • A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer. 
  • A phase II Hoosier Oncology Group study of vinorelbine and estramustine phosphate in hormone-refractory prostate cancer. 
  • A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer. 
  • A quantitative microscopic approach to predict local recurrence based on in vivo intraoperative imaging of sarcoma tumor margins. 
  • A randomized phase III comparative trial of immediate consolidation with high-dose chemotherapy and autologous peripheral blood progenitor cell support compared to observation with delayed consolidation in women with metastatic breast cancer and only bone metastases following intensive induction chemotherapy. 
  • ABL kinases promote breast cancer osteolytic metastasis by modulating tumor-bone interactions through TAZ and STAT5 signaling. 
  • ACR Appropriateness Criteria® Prostate Cancer-Pretreatment Detection, Surveillance, and Staging. 
  • Aberrant expression of tumor suppressor proteins in the Ewing family of tumors. 
  • Activating mutations of Gs protein in monostotic fibrous lesions of bone. 
  • Acute pancreatitis associated with administration of a nitric oxide synthase inhibitor in tumor-bearing dogs. 
  • Adjuvant chemotherapy for osteosarcoma may not increase survival after neoadjuvant chemotherapy and surgical resection. 
  • Adjuvant chemotherapy for osteosarcoma of the extremity. Long-term results of two consecutive prospective protocol studies. 
  • Adjuvant chemotherapy in nonmetastatic osteosarcoma: a Southwest Oncology Group Study. 
  • Advances in the treatment of tumors arising in bone. 
  • Aggressive (epithelioid) osteoblastoma arising in soft tissue. 
  • Allografts about the Knee in Young Patients with High-Grade Sarcoma. 
  • An Observational Study of Concomitant Use of Emerging Therapies and Denosumab or Zoledronic Acid in Prostate Cancer. 
  • Anterior chest wall mass in an elderly male. 
  • Arterial spin labeling blood flow magnetic resonance imaging for the characterization of metastatic renal cell carcinoma(1). 
  • Assessment of anatomic extent and biologic hazard of prostatic adenocarcinoma. 
  • Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC). 
  • Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel. 
  • Association between ratio of matrix metalloproteinase-1 and local recurrence, metastasis, and survival in human chondrosarcoma. 
  • Association between ratio of matrix metalloproteinase-1 to tissue inhibitor of metalloproteinase-1 and local recurrence, metastasis, and survival in human chondrosarcoma. 
  • Autopsy and grief: a case of transformative postmortem examination. 
  • BMP-2 inhibits tumor-initiating ability in human renal cancer stem cells and induces bone formation. 
  • Beta4 integrin promotes osteosarcoma metastasis and interacts with ezrin. 
  • Beyond Mirels: Factors Influencing Surgical Outcome of Metastasis to the Extremities in the Modern Era. 
  • Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. 
  • Bone and soft tissue lesions: diagnosis with combined H-1 MR imaging and P-31 MR spectroscopy. 
  • Bone cancer clinical practice guidelines. 
  • Bone cancer. 
  • Bone cancer. 
  • Bone cancer. 
  • Bone metastases from breast cancer: value of CT bone windows. 
  • Bone morphogenetic proteins are expressed by both bone-forming and non-bone-forming lesions. 
  • CT-Guided Bone Biopsies in Metastatic Castration-Resistant Prostate Cancer: Factors Predictive of Maximum Tumor Yield. 
  • CYP3A4/5 and pharmacogenetics in patients with sarcoma - Authors' reply. 
  • Cancer-related fatigue. 
  • Capromab Pendetide imaging of prostate cancer. 
  • Cartilage tumours and bone development: molecular pathology and possible therapeutic targets. 
  • Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687. 
  • Cavernous hemangioma of the skull presenting with subdural hematoma. Case report. 
  • Childhood cancer and occupational radiation exposure in parents. 
  • Chondrosarcoma of bone: analysis of 108 cases and evaluation for predictors of outcome. 
  • Choosing wisely: the American Society for Radiation Oncology's top 5 list. 
  • Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. 
  • Clinical reasoning and advanced practice privileges enable physical therapist point-of-care decisions in the military health care system: 3 clinical cases. 
  • Collagenase specificity in chondrosarcoma metastasis. 
  • Combination chemotherapy for osteosarcoma. 
  • Combination short-course preoperative irradiation, surgical resection, and reduced-field high-dose postoperative irradiation in the treatment of tumors involving the bone. 
  • Common genetic variants associated with telomere length confer risk for neuroblastoma and other childhood cancers. 
  • Comparison of two long-term chemotherapy regimens, with or without agents to modify skeletal repair, in multiple myeloma. 
  • Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer. 
  • Computed tomography of the hindfoot. 
  • Concordance of histopathologic and cytologic grading in musculoskeletal sarcomas: can grades obtained from analysis of the fine-needle aspirates serve as the basis for therapeutic decisions? 
  • Constitutive hedgehog signaling in chondrosarcoma up-regulates tumor cell proliferation. 
  • Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer. 
  • Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer. 
  • Current concepts. Cancer in children. 
  • Cytopathology of mesenchymal chondrosarcomas: a report and comparison of four patients. 
  • Cytoplasmic and/or nuclear accumulation of the beta-catenin protein is a frequent event in human osteosarcoma. 
  • Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. 
  • Dedifferentiated parosteal osteosarcoma with giant cell tumor component. 
  • Delayed activation of spinal microglia contributes to the maintenance of bone cancer pain in female Wistar rats via P2X7 receptor and IL-18. 
  • Deletions and point mutations of p16,p15 gene in primary tumors and tumor cell lines. 
  • Desmoplastic fibroma. 
  • Detection of minimal residual breast cancer in bone marrow. 
  • Development of a computer-aided diagnostic scheme for detection of interval changes in successive whole-body bone scans. 
  • Development of a method to isolate circulating tumor cells using mesenchymal-based capture. 
  • Developmental pathways in musculoskeletal neoplasia: involvement of the Indian Hedgehog-parathyroid hormone-related protein pathway. 
  • Differential gene expression profiling of aggressive and nonaggressive follicular carcinomas. 
  • Disruption of crosstalk between mesenchymal stromal and tumor cells in bone marrow as a therapeutic target to prevent metastatic bone disease. 
  • Early follow-up of a custom non-fluted diaphyseal press-fit tumour prosthesis. 
  • Economic evaluation of zoledronic acid versus pamidronate for the prevention of skeletal-related events in metastatic breast cancer and multiple myeloma. 
  • Effect of IL-1 on experimental bone/bone-marrow metastases. 
  • Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer. 
  • Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. 
  • Electrophoretic evaluation of sera from dogs with cancer. 
  • Epidermal growth factor receptor signaling promotes metastatic prostate cancer through microRNA-96-mediated downregulation of the tumor suppressor ETV6. 
  • Epithelioid and epithelial neoplasms of bone. 
  • Epithelioid osteosarcoma of bone. Immunocytochemical evidence suggesting divergent epithelial and mesenchymal differentiation in a primary osseous neoplasm. 
  • Estrogen receptor determination in percutaneous bone marrow biopsies of patients with metastatic breast cancer. 
  • Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer. 
  • Evaluation of the paracrine and endocrine effects of genitourinary tumor produced growth factors. 
  • Ewing's sarcoma of the hand. 
  • Ewing's sarcoma. 
  • Exploratory analysis of Fas gene polymorphisms in pediatric osteosarcoma patients. 
  • Expression of osteocalcin and its transcriptional regulators core-binding factor alpha 1 and MSX2 in osteoid-forming tumours. 
  • Extraskeletal myxoid chondrosarcoma of the knee. 
  • FOXO transcription factors control E2F1 transcriptional specificity and apoptotic function. 
  • Favorable response to nivolumab in a young adult patient with metastatic histiocytic sarcoma. 
  • Fibular osteochondroma presenting as chronic ankle sprain. 
  • Fine needle aspiration of osteogenic sarcoma metastatic to the lung. A report of four cases. 
  • Fine-needle aspiration diagnosis of medulloblastoma metastatic to the pelvis. 
  • Following the forgotten phosphorus. 
  • Free vascularized fibula in traumatic long bone defects and in limb salvaging following tumor resection: comparative study. 
  • Free vascularized fibular graft reconstruction of large skeletal defects after tumor resection. 
  • Free vascularized fibular grafts for reconstruction of skeletal defects. 
  • Frontal sinus osteoma removal with the ultrasonic bone aspirator. 
  • Gardner's syndrome with bone scintigraphic and CT demonstration. 
  • Genetic determinants of childhood and adult height associated with osteosarcoma risk. 
  • Giant cell tumor of rib masquerading as thymoma: a diagnostic pitfall in needle core biopsy of the mediastinum. 
  • Giant-cell tumor of the appendicular skeleton. 
  • Gli2 and p53 cooperate to regulate IGFBP-3- mediated chondrocyte apoptosis in the progression from benign to malignant cartilage tumors. 
  • Global reluctance to practice evidence-based medicine continues in the treatment of uncomplicated painful bone metastases despite level 1 evidence and practice guidelines. 
  • Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions. 
  • Histiocytoid hemangioma of the skin and scapula. A case report with electron microscopy and immunohistochemistry. 
  • Hormonal therapy in metastatic hypernephroma. 
  • Hyperlucent lung after radiation therapy. 
  • Iatrogenic lesions of soft tissue and bone. 
  • Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. 
  • Imaging appearances of the sternum and sternoclavicular joints. 
  • Imaging of primary Ewing sarcoma with 13N-L-glutamate. 
  • Imaging of primary multifocal osseous lymphoma. 
  • Incidence of anemia in children with solid tumors or Hodgkin disease. 
  • Increased expression of S100A6 is associated with decreased metastasis and inhibition of cell migration and anchorage independent growth in human osteosarcoma. 
  • Influence of trauma on the unusual distribution of metastases from carcinoma of the larynx. 
  • Inhibition of notch signaling induces neural differentiation in Ewing sarcoma. 
  • Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673. 
  • Integrating carthage-specific T1rho MRI into knee clinic diagnostic imaging. 
  • Internally administered isotopes in the treatment of solid malignancy. 
  • Intra-arterial cisplatin with or without radiation in limb-sparing for canine osteosarcoma. 
  • Intra-arterial cisplatinum in preparation for the limb salvage procedure. 
  • Intracranial metastatic adenocarcinoma of the prostate presenting as visual disturbance. 
  • Intrathoracic metastasis from an extrathoracic malignancy: a radiographic approach to patient evaluation. 
  • Invasiveness is associated with metastasis and decreased survival in hemangiopericytoma of the central nervous system. 
  • Involvement and targeted intervention of dysregulated Hedgehog signaling in osteosarcoma. 
  • Ipsilateral fibular slide grafts in the management of distal fibula lesions. 
  • Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital Database. 
  • Isolated musculocutaneous neuropathy caused by a proximal humeral exostosis. 
  • Ivory vertebra on 18F-sodium fluoride scan: an old sign in a new modality. 
  • Jaffe-Campanacci syndrome, revisited: detailed clinical and molecular analyses determine whether patients have neurofibromatosis type 1, coincidental manifestations, or a distinct disorder. 
  • Jaffe-Campanacci syndrome. A case report and review of the literature. 
  • Leg mass in a 61-year-old man. 
  • Lesions of bone and bladder cancer. 
  • Limb salvage procedures in children with osteosarcoma. 
  • Limited chemotherapy and shrinking field radiotherapy for Osteolymphoma (primary bone lymphoma): results from the trans-Tasman Radiation Oncology Group 99.04 and Australasian Leukaemia and Lymphoma Group LY02 prospective trial. 
  • Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. 
  • Local complications after limb-salvage surgery for pediatric bone tumours: a pictorial essay. 
  • Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer. 
  • Long-term survivors of childhood Ewing sarcoma: report from the childhood cancer survivor study. 
  • Longitudinal Trends in Costs of Palliative Radiation for Metastatic Prostate Cancer. 
  • Longitudinal follow-up of adult survivors of Ewing sarcoma: A report from the Childhood Cancer Survivor Study. 
  • Loss of EGFR signaling regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance. 
  • Loss of SPDEF and gain of TGFBI activity after androgen deprivation therapy promote EMT and bone metastasis of prostate cancer. 
  • Loss of p16(INK4a) expression correlates with decreased survival in pediatric osteosarcomas. 
  • Managing the complications of plasma cell myeloma. 
  • Marshall Urist Award. Interstitial collagenase gene expression correlates with in vitro invasion in human chondrosarcoma. 
  • Massive allografts in the treatment of osteosarcoma and Ewing sarcoma in children and adolescents. 
  • Mastoid osteoma: A case report and review of the literature. 
  • Mechanisms and management of bone pain. 
  • Mesenchymal Tumors Can Derive from Ng2/Cspg4-Expressing Pericytes with β-Catenin Modulating the Neoplastic Phenotype. 
  • Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. 
  • Metacarpal reconstruction with free autogenous cartilage and bone following tumor resection. A case report. 
  • Metastatic angiosarcoma with thrombocytopenia and intratumoral indium-111-platelet deposition. 
  • Metastatic squamous cell carcinoma with pseudoangiosarcomatous features and aberrant expression of vascular markers. 
  • Methylthioadenosine phosphorylase and activated insulin-like growth factor-1 receptor/insulin receptor: potential therapeutic targets in chordoma. 
  • Microsurgery in musculoskeletal oncology. 
  • Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using fluorine-18-FDG PET. 
  • Morbidity and mortality after treatment of Ewing sarcoma: A single-institution experience. 
  • Multifocal vascular lesions of bone: imaging characteristics. 
  • Multiple hereditary exostoses (MHE): elucidating the pathogenesis of a rare skeletal disorder through interdisciplinary research. 
  • Multiple myeloma diagnosed secondary to analysis of a lytic bone lesion encountered during Mohs micrographic surgery. 
  • Multiple relapses of Clostridium difficile-associated diarrhea in a cancer patient. Successful control with long-term cholestyramine therapy. 
  • Musculoskeletal case of the day. Giant cell tumor of the sacrum. 
  • Musculoskeletal case of the day. Periosteal (juxtacortical) chondroma. 
  • Musculoskeletal case of the day. Sarcomatous degeneration of Paget disease. 
  • NCCN Guidelines Insights: Bone Cancer, Version 2.2017. 
  • NOV (CCN3) regulation in the growth plate and CCN family member expression in cartilage neoplasia. 
  • National inpatient complications and outcomes after surgery for spinal metastasis from 1993-2002. 
  • New and emerging therapies for bone metastases in genitourinary cancers. 
  • New secrets behind bone metastasis. 
  • Noninvasive visualization of retinoblastoma growth and metastasis via bioluminescence imaging. 
  • Objective evaluation of bone metastases in prostate cancer: to what end? 
  • Oncogenic osteomalacia caused by phosphaturic mesenchymal tumor of the temporal bone. 
  • Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases. 
  • Opportunities for improving the therapeutic ratio for patients with sarcoma. 
  • Optical coherence tomography of choroidal osteoma in 22 cases: evidence for photoreceptor atrophy over the decalcified portion of the tumor. 
  • Optimal pediatric dosing of anti-platelet agents for pipeline stent embolization -a case report and review of the literature. 
  • Optimal use of radium-223 in patients with metastatic castration-resistant prostate cancer. 
  • Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. 
  • Osteoblastic metastases from astrocytomas: a report of two cases. 
  • Osteoid osteoma and osteoblastoma. 
  • Osteoid osteoma of the clavicle. 
  • Osteoid osteoma of the neck of the talus: percutaneous, computed tomography-guided technique for complete excision. 
  • Osteomalacia due to 1alpha,25-dihydroxycholecalciferol deficiency. Association with a giant cell tumor of bone. 
  • Osteoprotegerin in bone metastases: mathematical solution to the puzzle. 
  • Osteosarcoma after radiotherapy for prostate cancer. 
  • P-glycoprotein levels predict poor outcome in patients with osteosarcoma. 
  • PET imaging of osteosarcoma in dogs using a fluorine-18-labeled monoclonal antibody Fab fragment. 
  • PSA progression following radical prostatectomy and radiation therapy: new standards in the new Millennium. 
  • Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. 
  • Pain, PSA flare, and bone scan response in a patient with metastatic castration-resistant prostate cancer treated with radium-223, a case report. 
  • Palliative radiation therapy for bone metastases: Update of an ASTRO Evidence-Based Guideline. 
  • Palliative radiation therapy for metastatic Ewing sarcoma. 
  • Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. 
  • Palliative radiotherapy for prostate cancer. 
  • Parathyroid hormone-related protein regulates glioma-associated oncogene transcriptional activation: lessons learned from bone development and cartilage neoplasia. 
  • Patched-one or smoothened gene mutations are infrequent in chondrosarcoma. 
  • Pathologic fractures through nonossifying fibromas: is prophylactic treatment warranted? 
  • Pathological bone fractures in a 20-year old athletic male with multifocal solitary plasmacytoma of bone. 
  • Patient preferences for treatments to delay bone metastases. 
  • Patient, Caregiver, and Nurse Preferences for Treatments for Bone Metastases from Solid Tumors. 
  • Patterns of bisphosphonate use in the United States in the treatment of metastatic bone disease. 
  • Patterns of response and progression in bone and soft tissue during and after treatment with radium-223 for metastatic castrate-resistant prostate cancer. 
  • Pediatric radiation oncology. 
  • Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. 
  • Perinatal factors associated with clinical presentation of osteosarcoma in children and adolescents. 
  • Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone. 
  • Phase II evaluation of oral estramustine, oral etoposide, and intravenous paclitaxel in patients with hormone-sensitive prostate adenocarcinoma. 
  • Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinib. 
  • Phase II trial of diaziquone in anthracycline-resistant adult soft tissue and bone sarcoma patients: a Southeastern Cancer Study Group Trial. 
  • Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. 
  • Physical activity among adult survivors of childhood lower-extremity sarcoma. 
  • Physicians' preferences for bone metastases drug therapy in the United States. 
  • Poland's syndrome and lymphoma. 
  • Practice patterns and predictors of followup imaging after a negative bone scan in men with castration resistant prostate cancer: results from the SEARCH database. 
  • Predicting bone scan positivity after biochemical recurrence following radical prostatectomy in both hormone-naive men and patients receiving androgen-deprivation therapy: results from the SEARCH database. 
  • Predicting bone scan positivity in non-metastatic castration-resistant prostate cancer. 
  • Predictors of prostate cancer tissue acquisition by an undirected core bone marrow biopsy in metastatic castration-resistant prostate cancer--a Cancer and Leukemia Group B study. 
  • Presenting symptoms in patients referred to a multidisciplinary clinic for bone metastases. 
  • Prevalence of pain and analgesic use in men with metastatic prostate cancer using a patient-reported outcome measure. 
  • Primary Bone Lymphoma Exhibits a Favorable Prognosis and Distinct Gene Expression Signatures Resembling Diffuse Large B-Cell Lymphoma Derived From Centrocytes in the Germinal Center. 
  • Primary carcinoma of the upper urinary tract. Effect of primary and secondary therapy on survival. 
  • Primary chest wall tumors. 
  • Primary chondroid melanoma. 
  • Primary cilia attenuate hedgehog signalling in neoplastic chondrocytes. 
  • Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate. 
  • Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone- refractory prostate cancer: results from cancer and leukemia group B 150005/9480. 
  • Prostate cancer, version 1.2014. 
  • Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. 
  • Prostatic malignancy. 
  • Pseudoanaplastic giant cell tumor of bone. 
  • Quotient imaging with N-13 L-glutamate in osteogenic sarcoma: correlation with tumor viability. 
  • Ra-223 Treatment for Bone Metastases in Castrate-Resistant Prostate Cancer: Practical Management Issues for Patient Selection. 
  • Racial differences in pain during 1 year among women with metastatic breast cancer: a hazards analysis of interval-censored data. 
  • Radiation Therapy for Solitary Plasmacytoma and Multiple Myeloma: Guidelines From the International Lymphoma Radiation Oncology Group. 
  • Radiation therapy in the management of neuroblastoma: the Duke University Medical Center experience 1967-1984. 
  • Radical surgery versus radiation therapy in early prostatic carcinoma. 
  • Radioisotope bone scanning characteristics of metastatic skeletal deposits of prostatic adenocarcinoma. 
  • Radiologic demonstration of temporal development of bizarre parosteal osteochondromatous proliferation. 
  • Radiosurgical treatment for Ewing's sarcoma of the lumbar spine: case report. 
  • Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). 
  • Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer. 
  • Rapid detection of bone metastasis at thoracoabdominal CT: accuracy and efficiency of a new visualization algorithm. 
  • Rationale of technical requirements for NRG-BR001: The first NCI-sponsored trial of SBRT for the treatment of multiple metastases. 
  • Recurrent para-articular chondroma of the ankle: a case report. 
  • Registration of three-dimensional magnetic resonance and radionuclide skeletal images. 
  • Regression of extrafoveal choroidal osteoma following photodynamic therapy. 
  • Renal cell carcinoma metastatic to the mandible. 
  • Renal-cell carcinoma metastatic to great toe. 
  • Reply to F. Valcamonico et al. 
  • Reply to Second malignancies in Ewing sarcoma survivors. 
  • Response rate as an endpoint in clinical trials. 
  • Retinoblastoma metastatic to bone marrow. A case with florid spread. 
  • Rheumatologic manifestations of cancer. 
  • Sarcoma of bone and soft tissue following treatment of Hodgkin's disease. 
  • Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis. 
  • Sarcomas arising in Paget disease of bone: a clinicopathologic analysis of 70 cases. 
  • Secondary reconstruction after vascularized fibular transfer. 
  • Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. 
  • Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid. 
  • Skeletal disorders in malignant disease. 
  • Skeletal metastases of melanoma. 
  • Solitary osteochondroma of the clavicle. 
  • Solitary renal cell carcinoma metastasis to the hand: the need for wide excision or amputation. 
  • Staging non-small cell lung cancer with whole-body PET. 
  • Staging techniques for lung cancer. 
  • Sternal metastasis as first presentation of a well-differentiated papillary thyroid carcinoma. 
  • Stress fractures of the proximal tibia in runners. 
  • Successful revascularization for delayed presentation of radiation-induced distal upper extremity ischemia. 
  • Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program. 
  • Systemic doxorubicin and intraarterial cisplatin preoperative chemotherapy plus postoperative adjuvant chemotherapy in patients with osteosarcoma. 
  • TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis. 
  • TP53 intron 1 hotspot rearrangements are specific to sporadic osteosarcoma and can cause Li-Fraumeni syndrome. 
  • Tenascin-C expression and distribution in cultured human chondrocytes and chondrosarcoma cells. 
  • The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer. 
  • The Role of Reconstructive Surgery After Skeletal and Soft Tissue Sarcoma Resection. 
  • The clinical management of chondrosarcoma. 
  • The clinical significance of tenascin-C splice variant expression in chondrosarcoma. 
  • The combined use of the Ilizarov method and microsurgical techniques for limb salvage. 
  • The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance). 
  • The efficacy of postprostatectomy radiotherapy in patients with an isolated elevation of serum prostate-specific antigen. 
  • The evolution and understanding of skeletal complication endpoints in clinical trials of tumors with metastasis to the bone. 
  • The fibula-flexor hallucis longus osteomuscular flap. 
  • The nucleolar localization domain of the catalytic subunit of human telomerase. 
  • The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. 
  • The use of an expandable cage for corpectomy reconstruction of vertebral body tumors through a posterior extracavitary approach: a multicenter consecutive case series of prospectively followed patients. 
  • The value of a baseline bone scan in patients with newly diagnosed prostate cancer. 
  • The value of radionuclide bone imaging in selected patients with osteogenic sarcoma metastatic to lung. 
  • Toward a drug development path that targets metastatic progression in osteosarcoma. 
  • Traumatic pseudoaneurysm of the brachial artery caused by an osteochondroma, mimicking biceps rupture in a weightlifter: a case report. 
  • Treatment and outcome of 82 patients with angiosarcoma. 
  • Treatment dynamics of bone-targeting agents among men with bone metastases from prostate cancer in the United States. 
  • Treatment of osseous metastases in patients with renal cell carcinoma. 
  • Treatment of pathologic fracture of the humerus. 
  • Treatment options for patients with prostate cancer who develop metastatic disease after hormonal therapy. 
  • Treatment recommendations for primary extradural meningiomas. 
  • Two HLA Class II Gene Variants Are Independently Associated with Pediatric Osteosarcoma Risk. 
  • Unique and overlapping GLI1 and GLI2 transcriptional targets in neoplastic chondrocytes. 
  • Update of the international consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. 
  • Upper extremity compartmental anatomy: clinical relevance to radiologists. 
  • Urinary cyclic adenosine monophosphate as an aid in the diagnosis of hyperparathyroidism. 
  • Utility of fine-needle aspiration in the diagnosis of primary osteosarcoma. 
  • Validation of a bone scan positivity risk table in non-metastatic castration-resistant prostate cancer. 
  • Validation of the Brazilian version of the musculoskeletal tumor society rating scale for lower extremity bone sarcoma. 
  • Vascularized fibula-based physis transfer for pediatric proximal humerus reconstruction. 
  • Venous thoracic outlet syndrome secondary to first rib osteochondroma in a pediatric patient. 
• 

  Keywords of People

  • Charles, Hal Cecil, Associate Professor of Radiology, Radiology
  • Erickson, Harold Paul, James B. Duke Distinguished Professor of Cell Biology, Biomedical Engineering
  • Gottfried, Oren N, Professor of Neurosurgery, Neurosurgery
  • Hilton, Matthew James, Associate Professor in Orthopaedic Surgery, Cell Biology
  • Koontz, Bridget Fey, Associate Professor of Radiation Oncology, Radiation Oncology
  • Reiman Jr., Robert Ellis, Associate Professor of Radiology, Radiology
  • Sullivan, Daniel Carl, Professor Emeritus of Radiology, Radiology